Paris, France, September 15, 2022 – Tridek-One SAS, a biotech start-up and leader in the research and development of CD31 agonists to restore the immune balance, closed a € 16 million new round of financing led by Pureos Bioventures with participation of new investors bpifrance and Bioqube Ventures and historical investors AdBio Partners and Advent Life Sciences.
The funds will primarily be used to identify development candidates, to conduct IND enabling studies and to further build the organization.
Tridek-One appoints Laurence de Schoulepnikoff as Chief Executive Officer and Erik van den Berg as Chairman of the Board of Directors.